Marta de Lucas Sanz

Marta de Lucas Sanz

Auto-generated profile, based on publicly available information

Marta de Lucas Sanz

NORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2026 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
MRMahsa Rezaeipour
Mahsa Rezaeipour
MSMarta de Lucas Sanz
Marta de Lucas Sanz
HAHamed Allahverdi
Hamed Allahverdi
GTGaëlle Triballier
Gaëlle Triballier
EKEliane Klein
Eliane Klein
Anna GolebiewskaAnna Golebiewska
Anna Golebiewska
Introduction: Glioblastoma represents an aggressive, immunologically cold primary brain tumor largely unresponsive to conventional immunotherapies. Dissecting patient-specific immunosuppressive cues is limited by current preclinical models. Understanding the functional cross-talk between tumor and immune cells across distinct microenvironmental niches is crucial for advancing personalized immunotherapy. Methods: We assessed the immunogenic features of glioblastoma cells and cross-talk with T-cells using bulk and single-cell RNA-seq, multicolor flow cytometry, immunohistochemistry, and functional assays in patient tumors, patient-derived organoids (PDOs), orthotopic xenografts and cell cultures. We developed an advanced 3D co-culture system combining PDOs with human peripheral blood T-cells isolated from glioblastoma patients or healthy donor blood to functionally investigate T-cell behavior in a patient-specific context. T-cell subsets integrated and non-integrated into the PDOs were examined for T-cell activation, exhaustion, and T regulatory cell development in response to tumor-derived signals and hypoxia. Results: Single-cell RNA-seq-based crosstalk predicted direct ligand-receptor and soluble axes between glioblastoma and T-cells. Glioblastoma cells in patient tumors and diverse patient-derived models showed cell surface MHC class I expression across diverse genetic backgrounds and microenvironmental niches, modulable by interferon gamma. Subsets of CD4 + and CD8 + T-cells integrated into 3D PDOs deprived of myeloid component. PDO-integrated T-cells were enriched for T regulatory cells (Treg), and exhibited a heterogeneous spectrum of activation and dysfunction states, with differential expression of PD-1, LAG-3, TIM-3, CD45RO, Granzyme B, TCF1, and TOX. T-cells subjected to soluble factors were largely unaffected and retained capacity to reintegrate PDOs at sequential co-cultures. Hypoxia influenced T-cell phenotype, but did not prevent activation or infiltration within the early stages of co-culture. Conclusion: Our work provides insights into tumor-intrinsic cues of immune evasion in glioblastoma and introduces a scalable patient-relevant ex vivo platform for functional studies. Surface MHC-I was detectable in all assessed glioblastoma models; and was retained in contact with T-cells, indicating that MHC-I loss is not their predominant immune-escape mechanism. Immunosuppression occurred in direct contact with glioblastoma cells, involving both TOX-dependent exhaustion and TOX-independent dysfunction. Advanced co-cultures of glioblastoma PDOs may serve as a powerful tool for functional studies ex vivo, predicting clinically-relevant responses to immunotherapeutic treatments in the future.